MX2010007841A - Anticuerpos anti-trkb mejorados. - Google Patents

Anticuerpos anti-trkb mejorados.

Info

Publication number
MX2010007841A
MX2010007841A MX2010007841A MX2010007841A MX2010007841A MX 2010007841 A MX2010007841 A MX 2010007841A MX 2010007841 A MX2010007841 A MX 2010007841A MX 2010007841 A MX2010007841 A MX 2010007841A MX 2010007841 A MX2010007841 A MX 2010007841A
Authority
MX
Mexico
Prior art keywords
improved anti
trkb antibodies
polynucleotides
vectors
trkb
Prior art date
Application number
MX2010007841A
Other languages
English (en)
Inventor
Kenneth R Luehrsen
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc filed Critical Irm Llc
Publication of MX2010007841A publication Critical patent/MX2010007841A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona anticuerpos mejorados o moléculas de enlace de antígeno que reconocen específicamente y agonizan al receptor de cinasa receptora de tirosina B (TrkB), y métodos para su uso. En la invención también se proporcionan polinucleótidos y vectores que codifican estas moléculas, y células huésped que alojan a los polinucleótidos o a los vectores.
MX2010007841A 2008-01-17 2009-01-16 Anticuerpos anti-trkb mejorados. MX2010007841A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2182008P 2008-01-17 2008-01-17
PCT/US2009/031345 WO2009092049A1 (en) 2008-01-17 2009-01-16 Improved anti-trkb antibodies

Publications (1)

Publication Number Publication Date
MX2010007841A true MX2010007841A (es) 2010-09-28

Family

ID=40627621

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010007841A MX2010007841A (es) 2008-01-17 2009-01-16 Anticuerpos anti-trkb mejorados.

Country Status (15)

Country Link
US (1) US8642035B2 (es)
EP (1) EP2235062A1 (es)
JP (1) JP5420568B2 (es)
KR (1) KR101290503B1 (es)
CN (1) CN102015769B (es)
AR (1) AR070202A1 (es)
AU (1) AU2009205937B2 (es)
BR (1) BRPI0906877A2 (es)
CA (1) CA2712298C (es)
CL (1) CL2009000090A1 (es)
EA (1) EA028621B1 (es)
MX (1) MX2010007841A (es)
PE (1) PE20091326A1 (es)
TW (1) TW200936608A (es)
WO (1) WO2009092049A1 (es)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS53350B (en) 2008-09-22 2014-10-31 Array Biopharma, Inc. SUBSTITUTED COMPOUNDS OF IMIDASO [1,2-B] PYRIDASINE AS INK KINASE INHIBITORS
TWI577680B (zh) 2008-10-22 2017-04-11 亞雷生物製藥股份有限公司 作為ＴＲＫ激酶抑制劑之經取代吡唑并〔１，５－ａ〕嘧啶化合物
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
WO2011036297A2 (de) * 2009-09-27 2011-03-31 Ruhr-Universität-Bochum Verfahren zur therapie und diagnose von morbus alzheimer
ES2534335T3 (es) 2010-05-20 2015-04-21 Array Biopharma, Inc. Compuestos macrocíclicos como inhibidores de la Trk cinasa
ES2926988T3 (es) 2011-03-15 2022-10-31 X Body Inc Métodos de cribado de anticuerpos
CN102830228B (zh) * 2011-06-15 2015-01-21 格诺思博生物科技(上海)有限公司 定量分析循环肿瘤细胞的试剂及试剂盒
CN102944674B (zh) * 2012-11-05 2014-10-22 武汉远征世纪制药有限公司 一种检测TrkB受体pan-Tyr位点活性的ELISA试剂盒及其使用方法
EP3485882A1 (en) * 2013-01-25 2019-05-22 Case Western Reserve University Compositions for the treatment of pervasive development disorders
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US20160193231A1 (en) * 2013-06-26 2016-07-07 Rett Syndrome Research Trust Rett syndrome and treatments therefore
FI3699181T3 (fi) 2014-11-16 2023-03-28 Array Biopharma Inc Kiteinen muoto (s)-n-(5-((r)-2-(2,5-diluorifenyyli)-pyrrolidin-1-yyli)-pyratsolo[1,5-a]pyrimidin-3-yyli)-3-hydroksipyrrolidiini-1-karboksamidivetyysulfaatista
CN104524568B (zh) * 2015-01-08 2018-04-20 中国人民解放军第二军医大学 一种治疗肥胖症的药物组合物及其应用
US9869296B2 (en) 2015-05-07 2018-01-16 General Electric Company Attachment method and system to install components, such as tip extensions and winglets, to a wind turbine blade
US9869297B2 (en) 2015-05-07 2018-01-16 General Electric Company Attachment method and system to install components, such as vortex generators, to a wind turbine blade
US9869295B2 (en) 2015-05-07 2018-01-16 General Electric Company Attachment method to install components, such as tip extensions and winglets, to a wind turbine blade, as well as the wind turbine blade and component
CN107849615A (zh) 2015-06-01 2018-03-27 洛克索肿瘤学股份有限公司 诊断和治疗癌症的方法
DK3322706T3 (da) 2015-07-16 2021-02-01 Array Biopharma Inc Substituerede pyrazolo[1,5-a]pyridin-forbindelser som ret-kinaseinhibitorer
US10100805B2 (en) 2015-10-12 2018-10-16 General Electric Compant Tip extension assembly for a wind turbine rotor blade
MX2018005087A (es) 2015-10-26 2019-05-16 Loxo Oncology Inc Mutaciones puntuales en cáncer resistente a trk y métodos relacionados con las mismas.
CA3005491A1 (en) 2015-11-17 2017-05-26 Glaxosmithkline Intellectual Property Development Limited Binding agonists for treatment of neurological and other disorders
JP7061602B2 (ja) 2016-04-04 2022-04-28 ロクソ オンコロジー， インコーポレイテッド （Ｓ）－Ｎ－（５－（（Ｒ）－２－（２，５－ジフルオロフェニル）－ピロリジン－１－イル）－ピラゾロ［１，５－ａ］ピリミジン－３－イル）－３－ヒドロキシピロリジン－１－カルボキサミドの液体製剤
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
RU2751636C2 (ru) 2016-04-04 2021-07-15 Локсо Онколоджи, Инк. Способы лечения детских раковых заболеваний
DK3458456T3 (da) 2016-05-18 2020-12-14 Array Biopharma Inc Fremstilling af (s)-n-(5-((r)-2-(2,5-difluorphenyl)pyrrolidin-1-yl)pyrazol[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidin-1-carboxamid
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
AU2017342176A1 (en) * 2016-10-10 2019-05-02 The National Institute for Biotechnology in the Negev Ltd. Non-cytotoxic modified cells and use thereof
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
TW202300515A (zh) * 2016-10-20 2023-01-01 法商賽諾菲公司 抗ｃｈｉｋｖ抗體及其用途
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
US9914781B1 (en) 2016-11-08 2018-03-13 Glaxosmithkline Intellectual Property Development Limited Binding agonist for treatment of neurological and other disorders
US10443579B2 (en) 2016-11-15 2019-10-15 General Electric Company Tip extensions for wind turbine rotor blades and methods of installing same
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
CN110267960B (zh) 2017-01-18 2022-04-26 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡唑并[1,5-a]吡嗪化合物
US10830206B2 (en) 2017-02-03 2020-11-10 General Electric Company Methods for manufacturing wind turbine rotor blades and components thereof
US11098691B2 (en) 2017-02-03 2021-08-24 General Electric Company Methods for manufacturing wind turbine rotor blades and components thereof
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
SG11201911737PA (en) 2017-06-06 2020-01-30 Univ Massachusetts Self-regulating aav vectors for safe expression of mecp2 in rett syndrome
US10793634B2 (en) * 2017-06-09 2020-10-06 Boehringer Ingelheim International Gmbh Anti-TrkB antibodies
TWI812649B (zh) 2017-10-10 2023-08-21 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
CA3080157A1 (en) 2017-10-26 2019-05-02 Array Biopharma Inc. Formulations of a macrocyclic trk kinase inhibitor
US10773464B2 (en) 2017-11-21 2020-09-15 General Electric Company Method for manufacturing composite airfoils
US11668275B2 (en) 2017-11-21 2023-06-06 General Electric Company Methods for manufacturing an outer skin of a rotor blade
US11040503B2 (en) 2017-11-21 2021-06-22 General Electric Company Apparatus for manufacturing composite airfoils
US10865769B2 (en) 2017-11-21 2020-12-15 General Electric Company Methods for manufacturing wind turbine rotor blade panels having printed grid structures
US10920745B2 (en) 2017-11-21 2021-02-16 General Electric Company Wind turbine rotor blade components and methods of manufacturing the same
US10913216B2 (en) 2017-11-21 2021-02-09 General Electric Company Methods for manufacturing wind turbine rotor blade panels having printed grid structures
US11390013B2 (en) 2017-11-21 2022-07-19 General Electric Company Vacuum forming mold assembly and associated methods
US10821652B2 (en) 2017-11-21 2020-11-03 General Electric Company Vacuum forming mold assembly and method for creating a vacuum forming mold assembly
US11248582B2 (en) 2017-11-21 2022-02-15 General Electric Company Multiple material combinations for printed reinforcement structures of rotor blades
MX2020003550A (es) 2017-11-30 2020-08-03 Regeneron Pharma Anticuerpos monoclonales anti-trkb y metodos de uso.
EP3740491A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
JP7061195B2 (ja) 2018-01-18 2022-04-27 アレイ バイオファーマ インコーポレイテッド ＲＥＴキナーゼ阻害剤としての置換ピラゾロ［３，４－ｄ］ピリミジン化合物
US11472802B2 (en) 2018-01-18 2022-10-18 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors
CN108265036B (zh) * 2018-01-26 2021-04-27 山东大学齐鲁医院 一种沉默t1蛋白的重组病毒及其构建方法与应用
US10821696B2 (en) 2018-03-26 2020-11-03 General Electric Company Methods for manufacturing flatback airfoils for wind turbine rotor blades
US11035339B2 (en) 2018-03-26 2021-06-15 General Electric Company Shear web assembly interconnected with additive manufactured components
WO2019191659A1 (en) 2018-03-29 2019-10-03 Loxo Oncology, Inc. Treatment of trk-associated cancers
CN117281803A (zh) 2018-07-31 2023-12-26 罗索肿瘤学公司 喷雾干燥的分散体和制剂
CA3111984A1 (en) 2018-09-10 2020-03-19 Array Biopharma Inc. Fused heterocyclic compounds as ret kinase inhibitors
JP2022515198A (ja) 2018-12-19 2022-02-17 アレイ バイオファーマ インコーポレイテッド ＦＧＦＲチロシンキナーゼの阻害剤としての置換ピラゾロ［１，５－ａ］ピリジン化合物
WO2020131674A1 (en) 2018-12-19 2020-06-25 Array Biopharma Inc. 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22979A1 (es) 2000-12-08 2004-09-09 Centro Inmunologia Molecular Combinación inmunoterapéutica para el tratamiento de tumores que sobre-expresan receptores con actividad quinasa en residuos de tirosina
DE60305919T2 (de) * 2002-06-28 2007-01-18 Domantis Limited, Cambridge Dual-specifische liganden mit erhöhter halbwertszeit
CN101573381A (zh) * 2006-11-09 2009-11-04 Irm责任有限公司 激动剂TrkB抗体及其用途
JP2011501760A (ja) * 2007-10-23 2011-01-13 ノバルティス アーゲー 呼吸器疾患の処置のためのｔｒｋｂ抗体の使用

Also Published As

Publication number Publication date
WO2009092049A1 (en) 2009-07-23
CL2009000090A1 (es) 2009-07-24
EA201001139A1 (ru) 2011-04-29
CA2712298C (en) 2015-11-24
KR101290503B1 (ko) 2013-07-26
EA028621B1 (ru) 2017-12-29
CN102015769A (zh) 2011-04-13
CN102015769B (zh) 2014-12-10
US20110097326A1 (en) 2011-04-28
JP2011510021A (ja) 2011-03-31
AR070202A1 (es) 2010-03-17
CA2712298A1 (en) 2009-07-23
EP2235062A1 (en) 2010-10-06
AU2009205937B2 (en) 2013-02-07
US8642035B2 (en) 2014-02-04
TW200936608A (en) 2009-09-01
PE20091326A1 (es) 2009-09-18
JP5420568B2 (ja) 2014-02-19
KR20100103693A (ko) 2010-09-27
BRPI0906877A2 (pt) 2015-07-28
AU2009205937A1 (en) 2009-07-23

Similar Documents

Publication Publication Date Title
MX2010007841A (es) Anticuerpos anti-trkb mejorados.
JOP20190017A1 (ar) أجسام مضادة ترتبط مع مستقبل cgrp بشري
PH12019500600A1 (en) Antibodies against signal-regulatory protein alpha and methods of use
MX2022000302A (es) Moleculas de union que inhiben el crecimiento del cancer.
EA201100832A1 (ru) Варианты полипептидов рецептора iib активина и их применение
EA201001223A1 (ru) Стабилизированные белковые композиции
PH12015500806A1 (en) Binding molecules to the human ox40 receptor
MX2010008874A (es) Terapeuticos dirigidos a base de proteinas manipuladas que se unen al receptor de factor de crecimiento epidermico.
MX2010004374A (es) Armazones proteinicos.
MX2010008096A (es) Anticuerpos de ferroportina y metodos de uso.
MY155621A (en) Axl antibodies
ECSP11011072A (es) Antagonistas de los receptores tipo toll 3
WO2011047087A3 (en) Protein detection via nanoreporters
MX353984B (es) Anticuerpos multi-especificos.
MX2019015352A (es) Linfocitos t con receptor de antigeno quimerico (car) para receptor 1 huerfano tipo receptor de tirosina cinasa (ror 1).
MX2009009261A (es) Anticuerpos anti-ip-10 y metodos para su uso.
WO2008011107A3 (en) Antagonists of protease activated receptor-1 (par1)
IN2012DN05017A (es)
WO2011159928A3 (en) Anti-dr4 agonist antibodies
EA201171307A1 (ru) Антагонисты толл-подобного рецептора 3
WO2010141833A3 (en) Vital fluorochrome conjugates and methods of use
WO2021048564A3 (en) Antigen-binding domain
EP2488200A4 (en) APRIL ANTAGONISTS AND METHOD FOR THEIR USE
DE602006010187D1 (de) Einzelsequenzhybridisierungssonden
WO2010087997A3 (en) Cell lines expressing guanylate cyclase-c and methods of using them

Legal Events

Date Code Title Description
FG Grant or registration